WO2025104669 - ANTI-IL-1RAP CAR-T CELLS FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA
National phase entry is expected:
Publication Number
WO/2025/104669
Publication Date
22.05.2025
International Application No.
PCT/IB2024/061365
International Filing Date
14.11.2024
Title **
[English]
ANTI-IL-1RAP CAR-T CELLS FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA
[French]
CELLULES T-CAR ANTI-IL-1RAP POUR LE TRAITEMENT DE LA LEUCÉMIE MYÉLOÏDE AIGUË
Applicants **
ADVESYA
Inventors
SAINSON, Richard Charles Alfred
AUPEPIN DE LAMOTHE-DREUZY, Edouard
HASSKARL, Jens
JAEGER, Jonathan
FERRAND, Christophe
DESCHAMPS, Marina
Priority Data
63/599,180
15.11.2023
US
63/693,501
11.09.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2939 | |
| EPO | Filing, Examination, Granting | 13479 | |
| Japan | Filing, Examination, Granting | 2336 | |
| South Korea | Filing, Examination, Granting | 2345 | |
| USA | Filing, Examination, Granting | 5190 |
Total:
26,289
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The disclosure provides methods of treating a refractory or relapsed acute myeloid leukemia (AML) in a subject comprising administration of a cell comprising a nucleic acid molecule encoding a chimeric antigen receptor (CAR), wherein the CAR comprises an antibody or antigen-binding fragment thereof that binds IL-1RAP, a transmembrane domain, and an intracellular signaling domain comprising at least a stimulatory domain, wherein prior to administering the cell, the subject is preconditioned with a lymphodepleting chemotherapy (LDC).[French]
L'invention concerne des méthodes de traitement d'une leucémie myéloïde aiguë (LMA) réfractaire ou récidivante chez un sujet comprenant l'administration d'une cellule comportant une molécule d'acide nucléique codant pour un récepteur antigénique chimérique (CAR), le CAR comprenant un anticorps ou un fragment de liaison à l'antigène de celui-ci qui se lie à IL-1RAP, un domaine transmembranaire, et un domaine de signalisation intracellulaire comprenant au moins un domaine stimulateur, avant administration de la cellule, le sujet étant préconditionné avec une chimiothérapie lymphodéplétive (LDC).